India just got its first LAG-3-based dual immunotherapy for one of the deadliest skin cancers on the planet.
Bristol Myers Squibb has launched RELOPDUO — cleared by CDSCO for patients aged 12 and above battling unresectable or metastatic melanoma.
Translation: a brand-new lifeline where options have been brutally thin.
Think of your immune system as an army.
Cancer's favourite trick? Hitting the "pause" buttons on that army so the soldiers stand down.
Scientists call those pause buttons immune checkpoints.
For years, drugs targeted just one: PD-1.
RELOPDUO hits two at once:
Two brakes released. One army unleashed.
The approval leans on the RELATIVITY-047 Phase 2/3 trial.
The headline number that turned heads globally:
👉 Median progression-free survival of ~10.1 months with the combo, vs 4.6 months on nivolumab alone.
At 12 months, 47.7% of combo patients were still progression-free — compared to 36% on solo therapy.
And in longer follow-ups, median overall survival stretched past 51 months.
For metastatic melanoma, those numbers aren't incremental. They're a shift.
Melanoma is often called "rare" in India.
But rare is misleading.
Until now, Indian oncologists have been fighting this stage of the disease with a much smaller toolkit than their Western counterparts.
RELOPDUO closes that gap.
This isn't just a new drug launch.
It's the arrival of an entire new class of immunotherapy on Indian soil.
LAG-3 was the third checkpoint inhibitor class ever approved anywhere in the world — after PD-1 and CTLA-4.
And India now joins that map.
For a patient sitting in a Mumbai or Bengaluru oncology ward today, staring down stage IV melanoma, the conversation with their doctor just changed.
More options. Better odds. A little more time.
And sometimes, in oncology, a little more time is everything.
That's all for now!
